Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Endo USA Inc., a Keenova Therapeutics Company: Clinical Trials & FDA Approval Profile

Endo USA Inc., a Keenova Therapeutics Company (Global / Institutional) sponsors 16 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 2 active protocols (1 recruiting now), 13 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)6.3%
Median Closed Enrollment vs National (145 pts)165 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Endo USA Inc., a Keenova Therapeutics Company
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)16
Active Pipeline (Recruiting Now)2 (1)
Completed vs Stopped Early13 / 1 (6.3%)
Median Closed Actual Enrollment165 participants
Physical Hospital Site Disclosure32.1% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the Endo USA Inc., a Keenova Therapeutics Company Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI